Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.66 |
| ▸ | GRM5 | P41594 | 6/20 | 0.66 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.50 |
| ▸ | PKM | P14618 | 5/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 5/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7050312 | 0.86 | GRM5 (0.66) | NPC1RAB9AMAPTGRM5PLCG2 | |
| SCHEMBL6450512 | 0.86 | NPC1 (0.66) | NPC1RAB9AMAPTGRM5PLCG2 | |
| SCHEMBL6449824 | 0.84 | GRM5 (0.68) | NPC1RAB9AMAPTGRM5PLCG2 | |
| SCHEMBL4599223 | 0.82 | MAPT (0.54) | NPC1RAB9AMAPTGRM5SMN1; SMN2 | |
| SCHEMBL6451118 | 0.82 | TDP1 (0.45) | NPC1RAB9AMAPTGRM5SMN1; SMN2 | |
| SCHEMBL6454119 | 0.81 | SMN1; SMN2 (0.58) | NPC1RAB9AMAPTGRM5SMN1; SMN2 | |
| SCHEMBL5959921 | 0.80 | RAB9A (0.75) | NPC1RAB9AMAPTGRM5PLCG2 | |
| SCHEMBL6451961 | 0.80 | MEN1 (0.45) | NPC1RAB9AMAPTGRM5GAA | |
| SCHEMBL6453492 | 0.80 | MAPT (0.48) | NPC1RAB9AMAPTGRM5PLCG2 | |
| SCHEMBL2455727 | 0.80 | RAB9A (1.00) | NPC1RAB9AMAPTGRM5PLCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | NPC1 59/4885RAB9A 2483/4885MAPT 2805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.